4.2 Review

Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis

Journal

IMMUNOTHERAPY
Volume 4, Issue 10, Pages 1053-1061

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/IMT.12.117

Keywords

innate immunity; multiple sclerosis; plasmacytoid dendritic cells; Toll-like receptors; type I interferon

Categories

Funding

  1. National Institute of Neurological Disorders and Stroke [K23NS052553]
  2. Bayer Healthcare
  3. Biogen Idec
  4. TEVA Neuroscience

Ask authors/readers for more resources

Plasmacytoid dendritic cells (pDCs) are specialized APCs implicated in the pathogenesis of many human diseases. Compared with other peripheral blood mononuclear cells, pDCs express a high level of TLR9, which recognizes viral DNA at the initial phase of viral infection. Upon stimulation, these cells produce large amounts of type I interferon and other proinflammatory cytokines and are able to prime T lymphocytes. Thus, pDCs regulate innate and adaptive immune responses. This article reviews select aspects of pDC biology relevant to the disease pathogenesis and immunotherapy in multiple sclerosis. Many unresolved questions remain in this area, promising important future discoveries in pDC research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available